Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients
Descriptive Immunogenicity of 2 Doses of Pneumococcal 7-valent Conjugate Vaccine (Prevenar®, Wyeth Lederle) Followed by Pneumococcal Polysaccharide Vaccine (Pneumovax® Aventis Pasteur MSD) in Ataxia-telangiectasia Patients
Sponsor: Sheba Medical Center
A observational or N/A phase clinical study on Ataxia Telangiectasia, this trial is ongoing. The trial is conducted by Sheba Medical Center and has accumulated 11 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Unknown
-
Sep 2024 — Sep 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2021 — Jul 2024 [monthly]
Unknown Status
-
Jan 2021 — Dec 2021 [monthly]
Unknown Status
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
-
Jun 2018 — Nov 2020 [monthly]
Unknown Status
-
May 2018 — Jun 2018 [monthly]
Unknown Status
-
Apr 2018 — May 2018 [monthly]
Unknown Status
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Unknown Status NA
-
Jan 2017 — Aug 2017 [monthly]
Unknown Status NA
First recorded
Mar 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sheba Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .